European Journal of Medicinal Chemistry p. 357 - 372 (2019)
Update date:2022-08-03
Topics:
Liu, Hong-Min
Suo, Feng-Zhi
Li, Xiao-Bo
You, Ying-Hua
Lv, Chun-Tao
Zheng, Chen-Xing
Zhang, Guo-Chen
Liu, Yue-Jiao
Kang, Wen-Ting
Zheng, Yi-Chao
Xu, Hai-Wei
Lysine-specific demethylase 1 (LSD1), demethylase against mono- and di - methylated histone3 lysine 4, has emerged as a promising target in oncology. More specifically, it has been demonstrated as a key promoter in acute myeloid leukemia (AML), and several LSD1 inhibitors have already entered into clinical trials for the treatment of AML. In this paper, a series of new indole derivatives were designed and synthesized based on a lead compound obtained by a high-throughput screening with our in-house compound library. Among the synthetic compounds, 9e was characterized as a potent LSD1 inhibitor with an IC50 of 1.230 μM and can inhibit the proliferation of THP-1 cells effectively. And most importantly, this is the first irreversible LSD1 inhibitor that is not derived from monoamine oxidase inhibitors. Hence, the discovery of 9e may serve as a proof of concept work for AML treatment.
View Morewebsite:http://www.sincerityenterp.com
Contact:+86-571-88111846
Address:Binjiang Area, Hangzhou
Contact:+86-371-86058576
Address:NO.32, Jingsan Road, Zhengzhou, China
Nanjing Norris Pharm Technology Co., Ltd.
Contact:+86-13901585132
Address:2 Qiande Road, Jiangning sciencepark Hi-Tech Zone, Nanjing, P.R.China
Suzhou Tianma Specialty Chemicals Co.,Ltd
Contact:+86-512-68090577
Address:#199, Huayuan Rd, Mudu, Suzhou, Jiangsu, CHINA
YingYing Pharmaceutical Co.,Ltd
Contact:86-18854126208
Address:55#, yingxiongshan road
Doi:10.1016/0040-4039(95)01243-B
(1995)Doi:10.1002/ps.2780450306
(1995)Doi:10.1016/j.saa.2003.07.003
(2004)Doi:10.1021/ja00405a011
(1981)Doi:10.1016/j.tetlet.2007.05.083
(2007)Doi:10.1016/j.tetlet.2006.02.033
(2006)